ARGATROBAN IN DEXTROSE Drug Patent Profile
✉ Email this page to a colleague
When do Argatroban In Dextrose patents expire, and when can generic versions of Argatroban In Dextrose launch?
Argatroban In Dextrose is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in ARGATROBAN IN DEXTROSE is argatroban. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the argatroban profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Argatroban In Dextrose
A generic version of ARGATROBAN IN DEXTROSE was approved as argatroban by HIKMA PHARM CO LTD on January 5th, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ARGATROBAN IN DEXTROSE?
- What are the global sales for ARGATROBAN IN DEXTROSE?
- What is Average Wholesale Price for ARGATROBAN IN DEXTROSE?
Summary for ARGATROBAN IN DEXTROSE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 34 |
| DailyMed Link: | ARGATROBAN IN DEXTROSE at DailyMed |
Recent Clinical Trials for ARGATROBAN IN DEXTROSE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Veralox Therapeutics | Phase 2 |
| Veralox Therapeutics | Phase 1 |
| Celerion | Phase 1 |
US Patents and Regulatory Information for ARGATROBAN IN DEXTROSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | ARGATROBAN IN DEXTROSE | argatroban | SOLUTION;INTRAVENOUS | 201743-001 | May 9, 2011 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
